Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Nelipepimut-S (Primary) ; Sargramostim (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- 03 Jun 2019 Data from a preplanned analysis of this trial presented in a Sellas Life Sciences Group Media Release.
- 03 Jun 2019 According to a Sellas Life Sciences Group media release, data from a preplanned analysis of this trial was presented on June 2, 2019 at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO).
- 15 May 2019 According to a Sellas Life Sciences Group media release, immunologic response data from this study will be presented at the upcoming ASCO Annual Meeting (May 31st-June 4th, 2019 in Chicago, IL).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History